CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: Furthermore, serine contribution to glycine, GSH and GSSG was maintained in imatinib-treated primary CML CD34+ cells, while SHIN1, and consequently, combination of SHIN1 with imatinib, significantly reduced levels of relevant labelled fractions in GSH and GSSG (Fig. 5d, e and Supplementary Fig. 7d).